Economics - Conference Items
Permanent URI for this collection
Browse
Recent Submissions
Item The economic impact of inherited retinal diseases: asystematic literature review(2024) Willmington, Claire; Murphy, Aileen; Kirby, Ann; European CommissionAffecting over 2 million people worldwide, inherited retinal disease (IRD) is considered one of the leading causes of blindness among the working-age population. The recent market entry of Luxturna® to treat Leber Congenital Amaurosis (LCA) presents gene therapy as a promising option for IRD patients in the future. Furthermore, given the rarity of IRD and the high price of innovative medicines, it is essential to consider the current costs associated with IRD.Item The economic impact of neovascular age-related macular degeneration (AMD), diabetic retinopathy (DR) and diabetic macular edema (DME): a systematic literature review of the emerging literature(2024) Willmington, Claire; Murphy, Aileen; Kirby, Ann; European CommissionNeovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), as well as its consequence, such as diabetic macular edema (DME), are some of the leading causes of vision impairment in people aged 50 years and older. In the advanced stages of these conditions, treatment often relies on repeated intravitreal injections of anti-vascular endothelial growth factors (VEGFs), namely, ranibizumab, aflibercept faricimab, brolucizumab, and bevacizumab (off-label use). While the advent of VEGF injections changed the treatment landscape, Clinical trials investigating the therapeutic potential of gene therapy in nAMD, DR and DME show promising results and may inform future care provision. Given the high price of innovative medicines, it is essential to consider the economic costs associated with these conditions to inform resource allocation decisions.Item The economic impact of inherited retinal diseases: a systematic literature review(2024) Willmington, Claire; Murphy, Aileen; Kirby, Ann; European CommissionAffecting over 2 million people worldwide, inherited retinal disease (IRD) is considered one of the leading causes of blindness among the working-age population. The recent market entry of Luxturna® to treat Leber Congenital Amaurosis (LCA) presents gene therapy as a promising option for IRD patients in the future. Furthermore, given the rarity of IRD and the high price of innovative medicines, it is essential to consider the current costs associated with IRD.